Trials / Recruiting
RecruitingNCT07079423
Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis
Teclistamab for Newly Diagnosed Mayo Stage IIIB Light-chain Amyloidosis Patients, a Phase II Study
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II study in patients with newly diagnosed Mayo stage IIIB immunoglobulin light-chain (AL) Amyloidosis to evaluate the efficacy and safety of teclistamab
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teclistamab (Tec) | Teclistamab will be administered via a subcutaneous injection |
Timeline
- Start date
- 2025-06-28
- Primary completion
- 2027-01-31
- Completion
- 2027-12-31
- First posted
- 2025-07-23
- Last updated
- 2025-07-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07079423. Inclusion in this directory is not an endorsement.